2016 Hematological Malignancies

Abscopal Phase II Study Flowchart

relapsed/refractory cHL anti-PD1 pretreated

RE-Staging 1 POD: biopsy

PET-Staging 2 POD: biopsy

RT 20Gy w1d4-w3d2

Nivo

Nivo

Nivo Nivo

Nivo

Nivo Nivo Nivo Nivo

Nivo

Nivo

Nivo

w1d1

w3d1 w5d1 w7d1 w9d1 w11d1 w12

w24

Simon‘s two stage Optimal design (α=0.05):  H0: ARR <5%  will be rejected with 95% power if real ARR is ≥30%